Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study

NCT00469326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Atorvastatin

Sponsor

University Hospital, Motol